EGFR and non-small cell lung carcinoma: Recently, Nakagawa et al. suggested the histone deacetylase (HDAC) inhibitor vorinostat could circumvent EGFR-TKI resistance in EGFR-mutant NSCLC cell lines and in xenograft models [13].